Search
Research
The bone marrow microenvironment of pre-B acute lymphoblastic leukemia at single-cell resolutionThe bone marrow microenvironment (BMM) plays a key role in leukemia progression, but its molecular complexity in pre-B cell acute lymphoblastic leukemia (B-ALL), the most common cancer in children, remains poorly understood. To gain further insight, we used single-cell RNA sequencing to characterize the kinetics of the murine BMM during B-ALL progression.
Research
Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 ProtocolInfant acute lymphoblastic leukemia (ALL) is characterized by a high incidence of KMT2A gene rearrangements and poor outcome. We evaluated the value of minimal residual disease (MRD) in infants with KMT2A-rearranged ALL treated within the Interfant-06 protocol, which compared lymphoid-style consolidation (protocol IB) versus myeloid-style consolidation (araC, daunorubicin, etoposide/mitoxantrone, araC, etoposide).
News & Events
Researchers narrow down field of new treatments for most common childhood brain cancerCancer researchers have narrowed-down the field of immunotherapy drugs which could be used to tackle a form of childhood brain cancer.
News & Events
Why timing matters: How tumours respond to immunotherapy treatments over timeResearchers have identified key differences between cancers that respond to immunotherapy and those that do not.
News & Events
Lab results confirm promise of new immunotherapy gel for kids cancerNewly published research from The Kids Research Institute Australia and The University of Western Australia has found a gel applied during surgery to treat sarcoma tumours is both safe and highly effective at preventing the cancer from growing back.
News & Events
The Kids Cancer Researcher wins prestigious Cancer Council WA awardThe Kids Research Institute Australia cancer researcher, Dr Jason Waithman, has been named Cancer Council WA’s 2021 Cancer Researcher of the Year.
News & Events
'Natural killers' potential new cancer weaponThe Cancer Immunology team at The Kids is investigating how the body's 'natural killer' cells can be harnessed to fight cancer – whilst also protecting kids from nasty chemotherapy side effects.
Research
Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective mannerChemotherapy is included in treatment regimens for many solid cancers, but when administered as a single agent it is rarely curative. The addition of immune checkpoint therapy to standard chemotherapy regimens has improved response rates and increased survival in some cancers. However, most patients do not respond to treatment and immune checkpoint therapy can cause severe side effects. Therefore, there is a need for alternative immunomodulatory drugs that enhance chemotherapy.
Research
The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trialBRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma.
Research
Reproducible Bioinformatics Analysis Workflows for Detecting IGH Gene Fusions in B-Cell Acute Lymphoblastic Leukaemia PatientsB-cell acute lymphoblastic leukaemia (B-ALL) is characterised by diverse genomic alterations, the most frequent being gene fusions detected via transcriptomic analysis (mRNA-seq). Due to its hypervariable nature, gene fusions involving the Immunoglobulin Heavy Chain (IGH) locus can be difficult to detect with standard gene fusion calling algorithms and significant computational resources and analysis times are required. We aimed to optimize a gene fusion calling workflow to achieve best-case sensitivity for IGH gene fusion detection.